clioquinol has been researched along with Degenerative Diseases, Central Nervous System in 11 studies
Clioquinol: A potentially neurotoxic 8-hydroxyquinoline derivative long used as a topical anti-infective, intestinal antiamebic, and vaginal trichomonacide. The oral preparation has been shown to cause subacute myelo-optic neuropathy and has been banned worldwide.
5-chloro-7-iodoquinolin-8-ol : A monohydroxyquinoline that is quinolin-8-ol in which the hydrogens at positions 5 and 7 are replaced by chlorine and iodine, respectively. It has antibacterial and atifungal properties, and is used in creams for the treatment of skin infections. It has also been investigated as a chelator of copper and zinc ions for the possible treatment of Alzheimer's disease.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Clioquinol is a metal chelator that has beneficial effects in several cellular and animal models of neurodegenerative diseases as well as on Alzheimer disease patients." | 5.35 | The anti-neurodegeneration drug clioquinol inhibits the aging-associated protein CLK-1. ( Branicky, R; Carroll, M; Guimond, MP; Hayes, S; Hekimi, S; Hihi, A; McBride, K; Stepanyan, Z; Wang, Y, 2009) |
| "Clioquinol acts as a zinc and copper chelator." | 2.48 | Clioquinol: review of its mechanisms of action and clinical uses in neurodegenerative disorders. ( Bareggi, SR; Cornelli, U, 2012) |
| "Recently, dysphagia has attracted attention as a complication of SMON." | 1.48 | Tongue strength in patients with subacute myelo-optico-neuropathy. ( Ando, Y; Honda, S; Kimura, E; Konagaya, M; Nakama, T; Ueda, M; Yamashita, S, 2018) |
| " Here, a new series of orally bioavailable multifunctional antioxidants (MFAO-2s) possessing a 2-diacetylamino-5-hydroxypyrimidine moiety is described." | 1.42 | Orally Bioavailable Metal Chelators and Radical Scavengers: Multifunctional Antioxidants for the Coadjutant Treatment of Neurodegenerative Diseases. ( Kador, PF; Kawada, H, 2015) |
| "Clioquinol is a metal chelator that has beneficial effects in several cellular and animal models of neurodegenerative diseases as well as on Alzheimer disease patients." | 1.35 | The anti-neurodegeneration drug clioquinol inhibits the aging-associated protein CLK-1. ( Branicky, R; Carroll, M; Guimond, MP; Hayes, S; Hekimi, S; Hihi, A; McBride, K; Stepanyan, Z; Wang, Y, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (45.45) | 29.6817 |
| 2010's | 6 (54.55) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kawada, H | 1 |
| Kador, PF | 1 |
| Tardiff, DF | 1 |
| Brown, LE | 1 |
| Yan, X | 1 |
| Trilles, R | 1 |
| Jui, NT | 1 |
| Barrasa, MI | 1 |
| Caldwell, KA | 1 |
| Caldwell, GA | 1 |
| Schaus, SE | 1 |
| Lindquist, S | 1 |
| Chiem, K | 1 |
| Hue, F | 1 |
| Magallon, J | 1 |
| Tolmasky, ME | 1 |
| Yamashita, S | 1 |
| Nakama, T | 1 |
| Ueda, M | 1 |
| Honda, S | 1 |
| Kimura, E | 1 |
| Konagaya, M | 1 |
| Ando, Y | 1 |
| Perez, DR | 1 |
| Sklar, LA | 1 |
| Chigaev, A | 1 |
| Wang, Y | 1 |
| Branicky, R | 1 |
| Stepanyan, Z | 1 |
| Carroll, M | 1 |
| Guimond, MP | 1 |
| Hihi, A | 1 |
| Hayes, S | 1 |
| McBride, K | 1 |
| Hekimi, S | 1 |
| Cahoon, L | 1 |
| Bareggi, SR | 1 |
| Cornelli, U | 1 |
| Cole, GM | 1 |
| Barnham, KJ | 1 |
| Masters, CL | 1 |
| Bush, AI | 1 |
| McCarthy, AM | 1 |
3 reviews available for clioquinol and Degenerative Diseases, Central Nervous System
| Article | Year |
|---|---|
Clioquinol: To harm or heal.
Topics: Animals; Anti-Infective Agents; Asian People; ATP-Binding Cassette Transporters; Clioquinol; Cyclic | 2019 |
Clioquinol: review of its mechanisms of action and clinical uses in neurodegenerative disorders.
Topics: Animals; Clinical Trials as Topic; Clioquinol; Disease Models, Animal; Humans; Neurodegenerative Dis | 2012 |
Neurodegenerative diseases and oxidative stress.
Topics: Animals; Antioxidants; Clioquinol; Homeostasis; Humans; Metals; Neurodegenerative Diseases; Oxidativ | 2004 |
8 other studies available for clioquinol and Degenerative Diseases, Central Nervous System
| Article | Year |
|---|---|
Orally Bioavailable Metal Chelators and Radical Scavengers: Multifunctional Antioxidants for the Coadjutant Treatment of Neurodegenerative Diseases.
Topics: Alzheimer Disease; Animals; Antioxidants; Biological Availability; Brain; Cell Line, Tumor; Cell Sur | 2015 |
Dihydropyrimidine-Thiones and Clioquinol Synergize To Target β-Amyloid Cellular Pathologies through a Metal-Dependent Mechanism.
Topics: Amyloid beta-Peptides; Animals; Animals, Genetically Modified; Caenorhabditis elegans; Clioquinol; D | 2017 |
Inhibition of aminoglycoside 6'-N-acetyltransferase type Ib-mediated amikacin resistance by zinc complexed with clioquinol, an ionophore active against tumors and neurodegenerative diseases.
Topics: Acetyltransferases; Acinetobacter baumannii; Amikacin; Anti-Bacterial Agents; Antineoplastic Agents; | 2018 |
Tongue strength in patients with subacute myelo-optico-neuropathy.
Topics: Aged; Aged, 80 and over; Amyotrophic Lateral Sclerosis; Clioquinol; Deglutition Disorders; Female; H | 2018 |
The anti-neurodegeneration drug clioquinol inhibits the aging-associated protein CLK-1.
Topics: Aging; Animals; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Chelating Agents; Clioquino | 2009 |
The curious case of clioquinol.
Topics: Alzheimer Disease; Anti-Infective Agents, Local; Blindness; Clioquinol; Humans; Japan; Memory; Memor | 2009 |
Ironic fate: can a banned drug control metal heavies in neurodegenerative diseases?
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Alzheimer Disease; Animals; Clioquinol; Ferritins; Gen | 2003 |
Prana Biotechnology, Limited: metal attenuation in the treatment of neurodegenerative disease.
Topics: Alzheimer Disease; Animals; Biotechnology; Clioquinol; Copper; Metalloproteins; Mice; Neurodegenerat | 2004 |